Comparative Pharmacology
Head-to-head clinical analysis: LUFYLLIN versus VOSPIRE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUFYLLIN versus VOSPIRE ER.
LUFYLLIN vs VOSPIRE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.
Vospire ER (albuterol sulfate) is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via activation of adenylyl cyclase, leading to bronchodilation.
200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/mL injection, administer 200-400 mg IM or slow IV every 6-8 hours.
Oral: 30-60 mg once daily in the morning, with or without food. Maximum dose: 60 mg/day.
None Documented
None Documented
6-8 hours in adults with normal hepatic and renal function. In neonates, half-life is prolonged to 20-30 hours. In patients with hepatic cirrhosis, half-life may extend to 20-30 hours. In congestive heart failure, half-life is prolonged to 12-20 hours.
Terminal elimination half-life of vospire ER is approximately 12-15 hours. This prolonged half-life supports once-daily dosing and provides sustained bronchodilation over the dosing interval.
Primarily renal excretion of unchanged drug and metabolites. Approximately 50% is excreted unchanged in urine, with the remainder as metabolites (including 7-hydroxypropyltheophylline and 1,3-dimethyluric acid). Biliary/fecal elimination accounts for <10%.
Primarily renal (approximately 75% as unchanged drug and metabolites) and biliary/fecal (approximately 25%).
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator